Cardioprotective glucose-lowering drugs, statins, and risk of first-time atherosclerotic cardiovascular disease in Denmark: a nationwide cohort study.

ABSTRACT:

Background

We hypothesized that combining cardioprotective glucose-lowering drugs, i.e. sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists, and statins is associated with lower risk of first-time atherosclerotic cardiovascular disease (ASCVD) than using either drug alone.

Methods

We identified and followed individuals in Denmark with type 2 diabetes and without preexisting ASCVD from 2012 to 2021. In an active comparator design, individuals initiating a cardioprotective glucose-lowering drug or a dipeptidyl peptidase-4 inhibitor ± statin were compared: i) dipeptidyl peptidase-4 inhibitor (N = 12,298/59,795; 21%), ii) cardioprotective glucose-lowering drug (N = 16,357/59,795; 27%), iii) dipeptidyl peptidase-4 inhibitor plus statin (N = 14,8

SUBMITTER: Ternhamar T 

PROVIDER: S-EPMC12557563 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature